Hansa Biopharma Announces European Medicines Agency Accepts Marketing Authorization Application for IDEFIRIX™ (imlifidase)

LUND, Sweden, March. 1, 2019 /PRNewswire/ -- Hansa Biopharma AB (NASDAQ Stockholm: HNSA), the leader in immunomodulatory enzyme technology for rare IgG-mediated diseases, announced today that the European Medicines Agency (EMA) has accepted the Company's Marketing Authorization...

from PR Newswire: https://ift.tt/2EEHGIp